前收盘价格 | 5.49 |
收盘价格 | 5.66 |
成交量 | 48,789 |
平均成交量 (3个月) | 58,142 |
市值 | 56,501,220 |
市盈率 (P/E TTM) | 44.42 |
价格/销量 (P/S) | 2.97 |
股市价格/股市净资产 (P/B) | 5.12 |
52周波幅 | |
利润日期 | 6 Nov 2025 |
营业毛利率 | 5.16% |
营业利益率 (TTM) | 11.60% |
稀释每股收益 (EPS TTM) | 0.080 |
季度收入增长率 (YOY) | 38.50% |
总债务/股东权益 (D/E MRQ) | 14.28% |
流动比率 (MRQ) | 5.92 |
营业现金流 (OCF TTM) | -2.03 M |
杠杆自由现金流 (LFCF TTM) | -1.57 M |
资产报酬率 (ROA TTM) | 4.16% |
股东权益报酬率 (ROE TTM) | 9.17% |
市场趋势
短期 | 中期 | ||
行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
Medical Instruments & Supplies (全球的) | 混合的 | 看跌 | |
股票 | Nephros, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.8
分析师共识 | 1.5 |
内部交易活动 | NA |
价格波动 | -5.0 |
技术平均移动指标 | 2.5 |
技术振荡指标 | 4.0 |
平均 | 0.75 |
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. |
|
部门 | Healthcare |
行业 | Medical Instruments & Supplies |
投资方式 | Small Core |
内部持股比例 | 11.19% |
机构持股比例 | 44.01% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Mesirow Financial Investment Management, Inc. | 30 Jun 2025 | 13,800 |
52周波幅 | ||
中 | 6.00 (12.57%) | |
总计 | 1 购买 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Maxim Group | 08 Aug 2025 | 6.00 (12.57%) | 购买 | 3.90 |
该时间范围内无数据。
日期 | 类型 | 细节 |
---|---|---|
08 Oct 2025 | 公告 | Nephros Launches New PFAS Filter for Point-of-Use Protection of Potable Water |
07 Aug 2025 | 公告 | Nephros Announces Strong Second Quarter Financial Results |
31 Jul 2025 | 公告 | Nephros Schedules Second Quarter 2025 Financial Results Conference Call |
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合